Serum Institute of India Plans to Launch Covovax in June: Adar Poonawalla | India News
IBS Executive Director Adar Poonawalla said Saturday that his partnership for a Covid-19 vaccine with Novavax has shown excellent efficacy results.
“We have requested to start trials in India. We expect to launch Covocax by June 2021,” Poonawalla said in a tweet.
Our partnership for a COVID-19 vaccine with @Novavax has also posted excellent efficacy results. We also have ap… https://t.co/uAD3aGIckH
– Adar Poonawalla (@adarpoonawalla) 1611992590000
The new vaccine will be launched under the Covovax brand, which SII is manufacturing in association with Novovax. The Pune-based global vaccine giant has applied for DCGI’s permission to begin national testing of the new product.
The development comes shortly after the US-based biotech Novavax announced that its vaccine is 89.3% effective in preventing Covid-19 in a trial conducted in the UK.
The study evaluated the efficacy of the vaccine, NVX-CoV2373, during a period of high transmission and with a new variant strain of the virus in the UK emerging and circulating widely.
“NVX-CoV2373 has the potential to play an important role in solving this global public health crisis. We look forward to continuing to work with our partners, collaborators, researchers and regulators around the world to make the vaccine available as quickly as possible.” . Stanley C. Erck, president and CEO of Novavax, said in a statement on Friday.
Last year, Novavax had announced its partnership with IBS to produce 2 billion doses of the Covid-19 vaccine.